StockData
BioRestorative Therapies, Inc. logo

BioRestorative Therapies, Inc. (BRTX) stock

BRTXNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 8/30
$1.05−0.26 (-19.92%)

Close on Nov 20, 2026Market cap $26.73MP/E –Yield –

BioRestorative Therapies gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

BioRestorative Therapies's gross profit for the twelve months ending Mar 31, 2026 was $329.55K, down 8.5% year over year. For fiscal 2025 it was $335.86K, down 9.9% from the year before. The highest annual figure on record is $372.93K in fiscal 2024.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$335.86K-9.9%
FY2024Dec 31, 2024$372.93K+155.8%
FY2023Dec 31, 2023$145.80K+80.0%
FY2017Dec 31, 2017$81.00K+123.4%
FY2016Dec 31, 2016$36.25K-90.1%
FY2015Dec 31, 2015$367.41K+81.7%
FY2014Dec 31, 2014$202.16K+13633.8%
FY2013Dec 31, 2013$1.47K-89.7%
FY2012Dec 31, 2012$14.28K–
FY2011Dec 31, 2011$0–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2026Mar 31, 2026$15.79K-28.5%
Q4 FY2025Dec 31, 2025$17.96K-55.0%
Q3 FY2025Sep 30, 2025$1.23K-99.4%
Q2 FY2025Jun 30, 2025$294.57K+256.6%
Q1 FY2025Mar 31, 2025$22.09K-36.9%
Q4 FY2024Dec 31, 2024$39.96K+107.1%
Q3 FY2024Sep 30, 2024$215.36K+601.5%
Q2 FY2024Jun 30, 2024$82.61K+28.1%
Q1 FY2024Mar 31, 2024$35.00K-7.9%
Q4 FY2023Dec 31, 2023$19.30K+20.6%
Q3 FY2023Sep 30, 2023$30.70K+53.5%
Q2 FY2023Jun 30, 2023$64.50K+821.4%
Q4 FY2017Dec 31, 2017$38.00K+527.7%
Q3 FY2017Sep 30, 2017$16.00K+220.0%
Q2 FY2017Jun 30, 2017$20.00K+24.3%
Q1 FY2017Mar 31, 2017$7.00K–
Q4 FY2016Dec 31, 2016$6.05K–
Q3 FY2016Sep 30, 2016$5.00K–
Q2 FY2016Jun 30, 2016$16.08K–

More BioRestorative Therapies figures

See a number that looks wrong?